Brief: Aardvark Therapeutics Announces FDA Submission And Irb Approval Of Amended Trial Protocol
10/02/2026 15:29
Feb 10 (Reuters) - Aardvark Therapeutics Inc AARD.O: AARDVARK THERAPEUTICS ANNOUNCES FDA SUBMISSION AND IRB APPROVAL OF AMENDED TRIAL PROTOCOL FOR LEAD CANDIDATE ARD-101, EXPANDING ELIGIBILITY IN PHASE 3 STUDY OF PRADER-WILLI SYNDROME AARDVARK THERAPEUTICS INC - HERO TRIAL ENROLLMENT ON TRACK TO REPORT DATA Q3 2026 Source text: ID:nGNXLTFtB Further company coverage: AARD.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aardvark Therapeutics
See all newsBrief: Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., Mba, To Its Board Of Directors
Aardvark Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Aardvark Therapeutics Q2 operating expenses fall on paused ARD-101 clinical trials and workforce reduction
Aardvark Therapeutics, Inc. expected to post a loss of 87 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Intel, Nvidia, Aardvark